Building Digital Infrastructure for Quality Healthcare
In many emerging markets, ensuring the authenticity and quality of medicines remains a pressing public health challenge. RxAll is a health-tech company aiming to modernize the pharmaceutical supply chain, strengthen drug authentication, and empower pharmacies with digital tools. In this post, we explore RxAll’s mission, product ecosystem, real-world impact, and future trajectory in health technology and pharmaceutical innovation.
What Is RxAll?
RxAll (RxAll Inc.) is a medical technology / health information technology company founded in 2016 by Adebayo Alonge, Amy Kao, and Wei Liu, with headquarters in the U.S. and operations across Africa and beyond.
Its core mission is to ensure that “no one dies from counterfeit or substandard drugs anywhere in Africa.” RxAll seeks to create a digital infrastructure for healthcare that enables pharmacies, regulators, distributors, and patients to access, verify, and transact medicines in a reliable, transparent ecosystem
With business lines spanning hardware, software, logistics, and financing, RxAll positions itself as a full-stack solution in the pharmaceutical / healthtech sector — not just a device maker, but a platform driving systems change.
RxAll’s Core Solutions
RxAll’s offerings span several modules, each designed to address specific gaps in the pharmaceutical supply chain, pharmacy operations, and drug quality assurance.
RxScanner — Drug Authentication & Quality Verification
At the heart of RxAll’s proposition is RxScanner, a handheld spectrometry-based device integrated with AI and machine learning, which authenticates medicines in real time.
Key features of RxScanner:
Rapid, non-destructive drug testing: It can analyze a drug’s spectral signature without destroying the sample, delivering a quality assurance result in about 20 seconds via a mobile app interface (iOS/Android).
Offline functionality: Works without internet connectivity, which is crucial in low-connectivity environments
High accuracy and broad coverage: Its spectral library supports hundreds of drug types, often cited with ~99%+ accuracy or high confidence in distinguishing genuine vs. counterfeit or substandard medicines
Regulatory & supply chain use: It is used in post-marketing surveillance by regulators (e.g. NAFDAC in Nigeria) to screen imports and field samples, and in pharmacies and distributors to validate new batches.
Through RxScanner, RxAll effectively brings point-of-care verification — shifting drug quality assurance closer to the front lines of distribution and retail.
RxDelivered — Verified Medicine Delivery
RxAll’s RxDelivered is a logistics / e-commerce module that allows pharmacies and patients to order RxScanner-verified medicines online, delivered at wholesale or manufacturer-linked pricing.
This service bridges last-mile pharmaceutical logistics, ensuring that the medicines reaching patients are already validated, mitigating the risk of counterfeit products entering the consumer segment.
RxPOS, RxPay, and Marketplace Integration
To support pharmacy operations and systemic integration, RxAll offers additional software and financial modules:
RxPOS (Point-of-Sale / Pharmacy Management): Enables pharmacies to digitize sales, inventory control, procurement, record-keeping, and transaction processing.
RxPay: Embedded financing and payment solutions to help pharmacies deal with cash flow constraints, reduce stockouts, and smooth procurement cycles.
Marketplace / Verified Supplier Network: RxAll maintains a curated network of verified suppliers and manufacturers; only authenticated products pass through this marketplace, raising trust in procurement.
Together, these modules form a comprehensive pharmaceutical tech stack, enabling pharmacies to operate efficiently, transparently, and reliably.
Impact & Reach
RxAll has established meaningful traction and measurable impact in African health ecosystems and beyond.
Adoption & Reach Across Pharmacies
Over 4,000+ pharmacies in Africa use the RxAll platform and ecosystem
It powers operations in Nigeria, Kenya, Uganda, and other markets — enabling millions of patient interactions involving quality-verified medicines each month.
During the COVID-19 pandemic, pharmacies on RxAll’s digital infrastructure were able to spin up online sales / delivery channels, helping patients access quality medications safely at home.
Regulatory & Public Health Collaboration
In Nigeria, RxAll collaborates with NAFDAC to deploy RxScanner in post-marketing surveillance at checkpoints and ports. The device helps inspect imported and distributed drugs in situ.
RxScanner is used to authenticate 100,000+ drug samples per month in Nigeria as part of regulatory workflows and field screening.
The spectral library behind RxScanner includes hundreds of drug formulations, enabling meaningful coverage in local markets
Business Metrics & Growth
In the case of Ibadan Drug Fulfillment Center (IDFC), adoption of RxScanner in procurement led to claims of 50% growth in sales, aided by increased trust and differentiation.
RxAll’s model is based on leveraging deep tech (hyperspectral imaging, AI, IoT) applied to pharmaceutical quality assurance — positioning it at the intersection of healthtech, medtech, and supply chain innovation.
Investors and innovation ecosystems have recognized RxAll — it has won awards (e.g. Hello Tomorrow Global Deep Tech Award) and been featured in global innovation cohorts.
Technology & Innovation Backbone
Spectral Analysis + Machine Learning
RxAll combines hyperspectral / spectrometry-based imaging with machine learning and chemometrics to build a spectral fingerprint library for drugs. The system compares unknown samples against reference signatures to decide authenticity and quality.
Because the scanning is non-destructive, pharmacy or regulatory staff can test medicines without consuming or damaging the sample — a major advantage over traditional chemical assays
IoT & Data Infrastructure
Each scan is logged, timestamped, and stored on cloud-based infrastructure, allowing analytics, trend detection, and supply chain monitoring.
RxAll positions itself as more than a hardware company — its strength lies in the data network effect. As more pharmacies and regulators feed data into the system, the intelligence and detection capacity improve, enabling more proactive responses to counterfeit hotspots.
Platform Synergies
Because RxAll offers modules like POS, payments, marketplace, it can integrate authentication data, transaction data, and supplier verification under one roof. This synergy helps build trust, enable financing, and reduce leakage in the pharmaceutical value chain.
Future Outlook & Strategic Direction
Looking ahead, RxAll is poised to expand both geographically and functionally within healthtech and pharmaceutical ecosystems.
Geographic Expansion
RxAll is extending beyond West Africa into East Africa, Southeast Asia, and other markets with high counterfeit drug risk.The model is particularly well-suited to low- and middle-income countries where regulatory enforcement is challenged by resource constraints.
Deepening Vertical Integration
RxAll has potential to partner with local pharmaceutical manufacturers to introduce trusted generic lines, embed authentication from the point of manufacturing, and reduce dependence on importation.
Advanced Analytics & Surveillance
With large volumes of scan and transaction data, RxAll can build predictive algorithms and dashboards for regulators, mapping counterfeit drug flows, flagging anomalies, and driving targeted interventions.
Health Financing & Insurance Integration
Integrating with insurance, HMO systems, or health financing schemes could enable prescriptions to be automatically verified and paid, creating a seamless link between authentication, purchase, and reimbursement.
Standardization & Policy Engagement
As device-based authentication gains acceptance, RxAll can work alongside regulators and standard-setting bodies to establish protocols and policies that embed technologies like RxScanner into national pharmaceutical regulation frameworks.
Conclusion
RxAll represents a compelling and integrated answer to some of the most critical problems in health systems in emerging markets — from counterfeit medicines to fragmented pharmacy operations and opaque supply chains. By combining hardware (RxScanner), software (POS, payments, marketplace), logistics (RxDelivered), and data analytics, RxAll is building a sustainable digital pharmaceutical infrastructure.
Its adoption across thousands of pharmacies, collaboration with regulators, and consistent growth underscore its potential to transform how quality medicines are verified, distributed, and accessed. For stakeholders in global health, pharmaceutical regulation, medtech, and health innovation, RxAll serves as a model for how deep tech + systems integration can make meaningful inroads into persistent health system gaps.
